Summarized by Masters of Longevity from Longevity Technology.
Report from a major aging research meeting highlights calls for scientific rigor, prevention-focused policy, and building standardized clinical endpoints for aging trials.
Key Takeaways
- Harvard and ARDD leaders urged the field to adopt rigorous trials, real-world evidence, and validated biomarkers for longevity claims.
- ARPA-H launched PROSPR, a $144 million five-year program to harmonize data and develop a qualified clinical outcome assessment for aging.
- PROSPR defined intrinsic capacity as a core trial endpoint and harmonized 20 outcomes into stratified intrinsic capacity scores.
